This clinical trial is focused on studying treatments for patients with a type of cancer called gastric cancer and another type known as adenocarcinoma of the esophagogastric junction. These cancers affect the stomach and the area where the esophagus meets the stomach. The study is investigating the effectiveness and safety of a treatment combination that includes a medication called atezolizumab, which is also known by its code name RO5541267, in combination with a chemotherapy regimen called FLOT. FLOT is a combination of four drugs: fluorouracil, leucovorin, oxaliplatin, and docetaxel. The study will compare this combination to the FLOT regimen alone.
The purpose of the study is to see if adding atezolizumab to the FLOT regimen can improve outcomes for patients. Participants in the study will receive treatment over a period of up to 12 months. The study will monitor how well the cancer responds to the treatment and how long patients remain free from cancer progression or relapse after surgery. Some participants will receive the combination of atezolizumab and FLOT, while others will receive only the FLOT regimen. A placebo may be used in some cases to help compare the effects of the treatments.
Throughout the study, participants will undergo regular assessments to monitor their health and the status of their cancer. These assessments may include imaging tests like MRI or CT scans to check for changes in the cancer. The study aims to provide valuable information on whether the addition of atezolizumab can offer better outcomes for patients with these types of cancer. The trial is expected to continue until 2028, with the goal of improving treatment options for patients with gastric cancer and adenocarcinoma of the esophagogastric junction.
Germany 
